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Background: Cervical cancer is the major cause of morbidity and mortality in Thai women. Nevertheless, the
preventive strategy such as HPV vaccination program has not been implemented at the national level. This study
explored the HPV prevalence and genotypic distribution in a large cohort of Thai women.
Methods: A hospital-based cervical cancer screening program at Chulabhorn Hospital, Bangkok and a population-
based screening program at a rural Pathum Thani Province were conducted using liquid-based cytology and HPV
genotyping.
Results: Of 5906 women aged 20–70 years, Pap smear was abnormal in 4.9% and the overall HPV prevalence was
15.1%, with 6.4% high-risk (HR), 3.5% probable high-risk (PR), and 8.4% low-risk (LR) HPV. The prevalence and
genotypic distribution were not significantly different between the two cohorts. Among HR-HPV genotypes, HPV52
was the most frequent (1.6%), followed by HPV16 (1.4%), HPV51 (0.9%), HPV58 (0.8%), HPV18 (0.6%), and HPV39
(0.6%). Among LR-HPV genotypes, HPV72 and HPV62 were the most frequent while HPV6 and HPV11 were rare.
HPV infection was found to be proportionately high in young women, aged 20–30 years (25%) and decreasing with
age (11% in women aged >50). The more severe abnormal cytology results, the higher positivity of HR-HPV
infection was observed.
Conclusions: In conclusion, HPV52, HPV16, and HPV51 were identified as the most common HR-HPV genotypes in
Thai women. This study contributes genotypic evidence that should be essential for the development of appropriate
HPV vaccination program as part of Thailand’s cervical cancer prevention strategies.
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Cervical cancer is the third most common female cancer
worldwide after breast cancer and colon cancer with age
standardized incidence rate (ASR) of 14.0/100000
person-year [1]. Thailand is an endemic area of cervical
cancer with ASR of 17.8/100000 person-year [1]. Infec-
tion with human papillomavirus (HPV) is a causal and
necessary factor for the development of cervical cancer,
with its prevalence in cervical cancers of 99.7% [2-6]. As
a primary cervical cancer prevention, HPV vaccine has
been developed to protect against HPV16 and 18 infec-
tions which are commonly found in general population
and cervical cancer cases globally [7-11].
Since HPV genotypic distribution can be area-specific,
it is necessary to determine its genotypic distribution be-
fore establishing health care policies and vaccination
programs in each area [8,9]. This study was conducted
to assess the prevalence and characteristics of HPV ge-
notypes in Thai women as the cervical cancer prevalence
has been the highest in the past many decades. Two
steps were executed; Step 1 - a large hospital-based
study at Chulabhorn Hospital, Bangkok followed by Step
2 - a population-based study at Bangkhayaeng District,
Pathum Thani Province. The ultimate goal was to pro-
vide scientific evidence essential for the design and im-
plementation of Thailand’s cervical cancer prevention
policies.Materials and methods
Study population and enrollment
After approval by the Ethical Committee for Human Re-
search of Chulabhorn Hospital, the first hospital-based
study was performed among 4550 Thai females, aged
20–70 years, who were voluntarily registered into the
screening program at Chulabhorn Hospital, Bangkok,
Thailand during July 19, 2011 - November 5, 2012. Ex-
clusion criteria included absence of cervix, previous
HPV vaccine vaccination, history of abnormal cytology
or cervical intraepithelial neoplasia or cervical carcin-
oma, prior HPV infection, active disease for any types of
cancer during the last 5 years, or unable to receive
follow-ups throughout the program. Sixty-three women
were excluded. All participants received detailed infor-
mation regarding the study objectives and consented to
the study. Demographics, obstetric and gynecologic his-
tory, and cervical cancer screening data were collected.
The population-based study was subsequently under-
taken in the Bangkhayaeng District, Pathum Thani Prov-
ince using permanent living (named in the census
registration) or current living status in Bangkhayaeng
area at the day of pelvic examination to recruit a total of
1668 Thai females, aged 20–70 years who then under-
went cervical cancer screening during February 4-June16, 2013. Exclusion criteria were the same as our previ-
ous study.Sample collection and preparation
Samples were obtained using a cytobrush by gynecologic
oncologists or well-trained general practitioners for pel-
vic examination of Chulabhorn Hospital. The brush was
then placed in the preservative fluid in the BD SurePath
Pap test kit (BD Diagnostics-Tripath, Burlington, NC,
USA) for both liquid-based cytology and HPV DNA test-
ing. The investigators performing HPV typing were
blinded to cytology results. All cervical cytology slides
were interpreted per normal routine by qualified pathol-
ogists at Chulabhorn Hospital, using the Bethesda 2001
report system [12].HPV genotyping
For the identification of HPV genotypes, we used the
Linear array HPV testing (Roche, USA). This kit was
capable of identifying 37 HPV types including 12 high-
risk (HR), 8 probable high-risk (PR), and 17 low-risk
(LR) types those classified by oncogenic potentiality
[13-16]. In brief, 450-bp fragments from the L1 region
of the virus were first amplified by polymerase chain re-
action (PCR) of target DNA, followed by hybridization
using a reverse line blot system for simultaneous detec-
tion of up to 37 HPV genotypes (i.e., genotypes 6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56,
58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82,
83, 84, IS39, and CP6108).PCR amplification
Each 100 μL reaction consisted of 50 μL working master
mix and 50 μL of DNA sample. Amplification was per-
formed in an Applied Biosystems GeneAmp PCR System
9700 using the recommended parameters: 50°C for
2 min, 95°C for 9 min and 40 cycles of 95°C for 30 s,
55°C for 1 min, 72°C for 1 min and 72°C for 5 min be-
fore holding indefinitely at 72°C.Hybridization to the oligonucleotide probe
Following PCR amplification, the HPV and the ß-globin
amplicon were chemically denatured to form single
stranded DNA by addition of 100 μL Denaturation Solution.
Aliquots 100 μL of denatured amplicon were then trans-
ferred to the appropriate well of typing tray containing
hybridization buffer and single LINEAR ARRAY HPV
Genotyping Strip coated with HPV and ß-globin probe lines.
The biotin-labeled amplicon was hybridized to the oligo-
nucleotide probes only if the amplicon contained the match-
ing sequence of complementary probe.
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A blue colored complex precipitated at the probe posi-
tions where hybridization occurred. Then, the linear
array HPV genotyping strip was read visually by compar-
ing the pattern of blue lines to the linear array HPV
genotyping test reference guide.
Statistical analysis
Descriptive statistics were used to determine the distri-
bution types and frequencies of HPV positivity, age, and
cytology results. Frequency tables were done for qualita-
tive variables. Independent samples t-test was used com-
pare the means of age and Pearson’s chi-square test wereTable 1 Demographic characteristics of Thai women in two st
Demographics Total (N =5906) Chulabhorn ho
Age
Mean (years) 44.8 44.8
Median (years) 45.0 45.0
Range (years) 20-70 20-70
20-30 years (%) 634 (10.7) 481 (10.7)
31-70 years (%) 5272 (89.3) 4006 (89.3)
Parity†
Nulliparous 1867 (31.7) 1658 (36.9)
Multiparous 4019 (68.3) 2829 (63.1)
Menopause†
Pre-menopause 4012 (68.2) 3064 (68.3)
Post-menopause 1874 (31.8) 1423 (31.7)
Marital status
Single 1448 (24.5) 1319 (29.4)
Married 3619 (61.3) 2530 (56.4)
Divorced 839 (14.2) 638 (14.2)
Number of life-time sex partner(s)
0 (virgin) - 430 (9.6)
1 - 2827 (63.0)
1+ - 1230 (27.4)
Contraception use†
Yes 3002 (51.0) 2002 (44.6)
No 2884 (49.0) 2485 (55.4)
Education†
No education 56 (1.0) 27 (0.6)
Primary education 1319 (22.4) 678 (15.1)
High school 1025 (17.4) 651 (14.5)
Vocation school 820 (13.9) 650 (14.5)
Bachelor degree 2162 (36.7) 1991 (44.4)
Postgraduate 504 (8.6) 490 (10.9)
†missing data for Bangkayaeng Cohort 20 cases (1.4%).
1Independent samples t-test.
2Pearson’s chi-square test.
*p < 0.05.performed to verify the association of demographic data
and HPV prevalence between the two cohorts. p <0.05
was considered statistically significant. Licensed Stata
program version 12 was used for analysis.
Results
Demographic characteristics of 5906 Thai women
Demographic characteristics of 2 cervical cancer screen-
ing populations were shown in Table 1. Of 5906 women,
the median age was 45 years with a range of 20–70
years. Approximately two-thirds of them were pre-
menopausal and had prior pregnancy history. The pro-
portion of those having children and being married wasudy cohorts
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Hospital cohort. Women in the Bangkhayaeng District
were of lower educational level as compared to the
Chulabhorn Hospital cohort.
HPV prevalence and genotypic distribution
Table 2 demonstrates the overall HPV prevalence among
5906 Thai women was 15.1%, with 6.4% high risk (HR),
3.5% probable high risk (PR), and 8.4% low risk (LR)
HPV. No significant difference was identified on the
HPV prevalence between the two cohorts (p = 0.178).
Overall, the most frequent HR-HPV types consisted of
HPV52 (1.6%), HPV16 (1.4%), HPV51 (0.9%), HPV58
(0.8%), HPV18 (0.6%), and HPV39 (0.6%). Common PR-
HPV types were HPV70 (1.0%), HPV66 (0.8%), HPV53
(0.8%), and HPV68 (0.6%). LR-HPV subtypes were
HPV72 (2.5%), HPV62 (1.7%), HPV84 (1.1%), HPV71
(1.0%), and HPV61 (0.6%) (Figure 1).
Figure 2 shows the distribution of HR-HPV prevalence
in each cohort. The most common HR-HPV in Chulab-
horn Hospital Cohort was HPV52, 16, 51, 58, 39 and 18
(26%, 21.2%, 12.7%, 12.7%, 10.6%, and 9.2%, respect-
ively). The most common HR-HPV in Bangkhayaeng
District Cohort was HPV16, 51, 52, 58, 18 and 59
(21.4%, 21.4%, 21.4%, 12.7%, 9.5%, and 6.2%,
respectively).
Age-specific prevalence of HPV infection and abnormal
Pap smear
Pap smear was abnormal in 4.9% of the population. The
abnormal Pap smear rate was highest in those young
women aged 20–30 years (6.6%) and decreased by ad-
vancing age (Table 3). In addition, HPV infection was
found most frequent among women aged < 30 years,
with the prevalence of 24.8% (13.2% of HR-HPV), and
decreased by increasing age.
HPV infection frequency and abnormal cervical cytology
The HPV positivity rates in cases with atypical squa-
mous cells of undetermined significance (ASC-US)





Negative 5016 (84.9) 3795 (84.6)
Positive 890 (15.1) 692 (15.4)
High risk HPV† 376 (6.4) 292 (6.5)
Probable HR HPV† 204 (3.5) 156 (3.5)
Low risk HPV† 495 (8.4) 394 (8.8)
†Number (%), as individual type.high-grade squamous intraepithelial lesion (ASC-H) (n
= 11, 0.2%), low grade squamous intraepithelial lesion
(LSIL) (n = 66, 1.1%), and high grade squamous intrae-
pithelial lesion (HSIL) (n = 20, 0.3%) was 31.2%, 45.5%,
86.4% and 90.0%, respectively. The more severe cyto-
logical result, the higher HPV-positive proportion was
found.HPV, HR-HPV positive samples with normal cy-
tology in 5614 women amounted to 13.3%, 5.1%, re-
spectively. The most common HR-HPV type was
HPV52 (1.4%), HPV16 (0.9%), HPV51 (0.6%), HPV58
(0.6%), HPV18 (0.5%), and HPV39 (0.5%), respectively.
The overall HPV prevalence in 292 women with abnor-
mal cytology was 48.6% (HR-HPV 31.2%).The most
common HR-HPV types in this group included HPV16
(9.6%), HPV51 (6.9%), HPV52 (5.8%), HPV58 (3.8%),
HPV59 (3.4%), and HPV18 (2.4%) as shown in Figure 3.
Discussion
We investigated the prevalence and distribution of HPV
genotypes among 5906 Thai women enrolled for cervical
cancer screening at Chulabhorn Hospital, Bangkok, or
Bangkhayaeng District, Pathum Thani and revealed the
15% HPV infection rate among these women. The over-
all prevalence in both hospital-based and population-
based cohorts was not statistically different despite the
significant differences in the cohorts’ demographic char-
acteristics as shown in Table 1. The rural Bangkhayaeng
District appeared to comprise more uneducated, multip-
arous, and married women than the Chulabhorn
Hospital-based cohort in Bangkok. The genotypic data
was not different between the two cohorts suggesting
that the rate and type of HPV infections in Thai women
in this study were comparable regardless of their geo-
graphic locations and education levels. However, larger
studies involving more sub-regions of Thailand may be
needed.
Major studies from the Western countries reported
the prevalence of HR-HPV infections around 11.3%-
18.3% which were higher than our results [17-21]. Dis-
parate data from three previous studies conducted in
Thailand currently exist showed the lower prevalence ofrolled at Chulabhorn hospital or Bangkhayaeng district









Figure 1 Overall HPV genotyping in 5906 Thai females.
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different genotypic methods utilized in each study
[22-24]. A study by the National Cancer Institute of
Thailand reported the overall prevalence of 13 HPV ge-
notypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
of 8.2% by Hybrid Capture 2 hybridization assay method
without specific genotypic data [22]. Another Thai study
utilizing polymerase chain reaction (PCR) for E1 amplifi-
cation for 20 HPV genotypes (HR type 16, 18, 30, 31, 33,
35, 39, 42, 45, 51, 52, 56, 58, 59, 68, 73, 82, PR type 66,
and LR type 6, 11) found the HPV prevalence of 8.7%
among 1662 women in the screening setting [23]. The
higher HPV prevalence in our cohort that differs from
other Thai cohorts may reflect our more comprehensive
genotypic analysis that was aimed to detect more HPV
genotypes (37 genotypes) than other Thai studies,
regardless of cervical cancer risk categories. Neverthe-
less, the HR-HPV prevalence in this study of 6.4%
was comparable to most previously reported Thai
studies [22-24].
With respect to the HR-HPV genotypes that are the
major risk factors for cervical cancer, it was of interest
to find that in our Chulabhorn Hospital Cohort, the
most common genotype was HPV52 followed by HPV16
and HPV51. This finding was in contrast to most studies
in the Western countries and two smaller studies in
Thailand in which HPV16 was identified as the mostfrequent [23,24]. Nevertheless, HPV16 and HPV51 were
also well represented together with HPV52 as the top
HR-HPV genotypes in our Bangkhayaeng District
Cohort. When classified by continents, it was observed
that HPV16 was the first top-ranking HPV genotype as
shown in Table 4, whereas the second and other subse-
quent rankings were distinctively changed according to
each region [9]. For instance, HPV52 and HPV31 were
the second top-rankings in Africa and Europe, respect-
ively. Meanwhile, in the Asia continent, the most com-
monly found HPV included HPV16, HPV18, and
HPV52, with the prevalence of 2.5%, 1.4% and 0.7%, re-
spectively [25-32]. Parkin et al. studied the HPV preva-
lence in a normal cytology group of 28998 Eastern Asian
female cases and revealed that the most common HR-
HPV types were HPV16, HPV52, HPV58, HPV18,
HPV56, and HPV51, with the prevalence of 2.7%, 1.3%,
1.2%, 0.7%, 0.7%, 0.7%, respectively [27]. A study in
China also showed a high frequency of HPV16, HPV52,
HPV58, and HPV18 [26]. Bruni et al. performed meta-
analysis on HPV prevalence in one million normal cy-
tology woman which showed HR-HPV infection rate of
11.7% and the five most common HR-HPV types world-
wide were HPV16 (3.2%), HPV18 (1.4%), HPV52 (0.9%),
HPV31 (0.8%), and HPV58 (0.7%) [9]. Recently, Zhao
et al. reported that the most commonly HR-HPV in cer-
vical specimens at baseline from Chinese women aged
Figure 2 HR-HPV prevalence in 2 cohorts.
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[33]. Interestingly, HPV18, the most frequently detected
HR-HPV after HPV16 worldwide, was surprisingly un-
common in our study population. Our data is consistent
with results from previous Thai studies that reported a
very low prevalence of HPV18 [23,24].Table 3 HPV prevalence and risk groups among 5906 women
HPV Type Age range (year)
20-30 31-40 41-50 51-6
N 634 1479 1936 136
Pap smear results
Normal 592 (93.4) 1403 (94.9) 1835 (94.8) 131
Abnormal 42 (6.6) 76 (5.1) 101 (5.2) 56 (
HPV results
HPV negative 477 (75.2) 1221 (82.6) 1666 (86.1) 121
HPV positive 157 (24.8) 258 (17.4) 270 (13.9) 151
High risk HPV 84 (13.2) 126 (8.5) 101 (5.2) 50 (
Probable HR 43 (6.8) 64 (4.3) 61 (3.2) 26 (
Low risk HPV 76 (12.0) 124 (8.4) 157 (8.1) 103
•HR: High risk, PR: probable HR, LR: low risk.
•Values given as number (percentage) as individual type.When considering the significance of HPV52 in Thai
women compared to worldwide invasive cancer cases in
the meta-analysis of 30848 cases from 243 studies, the
prevalence of global HR-HPV was 89.9%, with HPV16
and HPV18 as the most common types, followed by





8 489 5906 5614 (95.1) 292 (4.9)
2 (95.9) 472 (96.5) 5614 (95.1) - -
4.1) 17 (3.5) 292 (4.9) - -
7 (89.0) 435 (89.0) 5016 (84.9) 4866 (86.7) 150 (51.4)
(11.0) 54 (11.0) 890 (15.1) 748 (13.3) 142 (48.6)
3.7) 15 (3.1) 376 (6.4) 285 (5.1) 91 (31.2)
1.9) 10 (2.0) 204 (3.5) 169 (3.0) 35 (12.0)
(7.5) 35 (7.2) 495 (8.4) 431 (7.7) 64 (21.9)
Figure 3 HR-HPV genotyping in normal and abnormal cytology.
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mal cytology, about half of them had HPV infections
and the most common HR-HPV types continued to be
the common HR-HPV types found in the normal cy-
tology cases, including HPV16, HPV51, HPV52 followed
by HPV58, HPV59, and HPV18, respectively. HPV52
was also frequently identified in two small cervical can-
cer studies reported from Thailand [34,35]. A study by
Thai NCI in 155 cases of cervical cancer showed that
the most commonly identified types were HPV16,
HPV18, HPV52, HPV58, and HPV33 [35]. Similar re-
sults from a study by Chiang Mai University Hospital in
the Northern Thailand in 99 cases of cervical cancer
showed that the most frequently found HR-HPV con-
sisted of HPV16, HPV52, HPV18, HPV33, and HPV58
[34]. HPV52 thus plays an important role in the Thai
population.
HPV prevalence is strongly associated with age world-
wide [8,9]. We noted a decline in the HPV prevalence,
both HR-HPV and non-HR-HPV genotypes, with in-
creasing age of the women in this study. It is also of
interest to find a lower rate of HPV infection (24.8%)
and HR-HPV genotypes (13.2%) in our young population
aged <30 years as compared to worldwide or Western
continent data, which showed a higher HR-HPV preva-
lence of 20-30% in women aged <30 years [8,9]. A
follow-up study of these young women is presently on-
going to determine the natural history of HPV infectionsin this particular subgroup. Moreover, 13.3% of women
in our study had HPV infection despite negative cytology
results. This data was comparable to a meta-analysis
performed by de Sanjose et al. which showed HR-HPV
prevalence of 10.4% in women with negative cytology re-
sults [8]. These women infected with HPV despite nega-
tive cytology results are also being followed to assess the
persistence of HPV and CIN development.
Future cervical cancer screening is moving towards
HPV-based screening because of its very high sensitivity
[36-38]. A randomized control study by Mayrand et al.
in 10154 women showed that HPV testing alone had a
higher sensitivity (94.6%) for detection of CIN2+ when
compared to conventional Pap smears (55.4%) [36]. In a
country with a low prevalence of HR-HPV as Thailand,
primary HR-HPV testing would have a high yield be-
cause the positive rate is not too high and will not lead
to overwhelming referral for secondary triage or even
colposcopy. Pap smear of unnecessary cases could be
possibly reduced by 93.6%.
In conclusion, this study represents the largest report
from Thailand with respect to detailed and comprehen-
sive genotypic analysis of HPV subtypes. The prevalence
and genotypic distribution of HPV did not significantly
differ between hospital-based and population-based co-
horts. HPV52 was the most frequently identified high-
risk genotype in Thai women followed by HPV16 and
HPV51. The majority of Thai women undergoing
Table 4 Comparison of HR-HPV prevalence and genotypic distribution in screening settings in various countries
Study/
year
Site/N HPV Test HR-
HPV*





USA PCR 13444 4507 881 1757 524 479 306 734 26 2009 437 865 919
2009 73371 (18.3) (33.5) (6.6) (13.1) (3.9) (3.6) (2.3) (5.5) (0.2) (14.9) (3.3) (6.4) (6.8)
Dickson
EL (16) **
USA PCR 11.9% 4.1% 0.7% 1.9% 0.4% 0.3% 0.5% - 2.1% - 1.1% 0.8%
2013 309471 (100) (34.5) (5.9) (16.0) (3.4) (2.5) - (4.2) (17.6) (9.2) (6.7)
Agarossi A
(17)
Italy HC2 followed by PCR 1403 415 150 211 61 67 111 68 132 67 142 120 45
2009 9946 (14.1) (29.6) (10.7) (15.0) (4.3) (4.8) (7.9) (4.8) (9.4) (4.8) (10.1) (8.6) (3.2)
Anderson
L (18) **
Ireland Cobas4800 test followed by Linear
array
16.6% 3.2% 1.2% 1.8% 1.2% 0.5% 1.2% 1.0% 1.6% 1.5% 1.0% 0.8% 1.6%
2012 5712 (100) (19.3) (7.2) (10.8) (7.2) (3.0) (7.2) (6.0) (9.6) (9.0) (6.0) (4.8) (9.6)
Ucakar V
(19)
Slovenia HC2/Real Time PCR followed by
Linear array
502 155 46 114 32 9 50 42 81 78 31 29 29
2012 4431 (11.3) (30.9) (9.2) (22.7) (6.4) (1.8) (10.0) (8.4) (16.1) (15.5) (6.2) (5.8) (5.8)
INOUE M
(23)
Japan HC2 followed by HPVDNAChip
(Biomedlab Co., South Korea)
632 167 73 50 17 7 43 20 98 189 100 131 39
2006 8156 (7.7) (22.7) (9.9) (6.8) (2.3) (1.0) (5.9) (2.7) (13.3) (25.7) (13.6) (17.8) (5.3)
Li H (24) China HPV GenoArray (Hybribio, Hong
Kong)
755 233 64 26 30 3 44 9 20 163 27 119 17
2013 3640 (20.7) (30.9) (8.5) (3.4) (4.0) (0.4) (5.8) (1.2) (2.6) (21.5) (3.6) (15.8) (2.3)
Zhoa FH
(31)
China SPF PCR-DEIA-LiPA (LaboBiomedial
Product, Rijswijk, the Netherlands)
924 222 74 59 65 31 81 33 102 243 69 90 22
2014 6035 (15.3) (3.7) (1.2) (1.0) (1.1) (0.5) (1.3) (0.5) (1.7) (4.0) (1.1) (1.5) (0.4)
This study Thailand Linear array (Roche, USA) 376 80 35 18 13 7 33 11 55 94 19 47 18
2015 5906 (6.4) (21.2) (9.3) (4.8) (3.5) (1.9) (8.8) (2.9) (14.6) (25.0) (5.1) (12.5) (4.8)
*HR-HPV included 12 HPV types as 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
**Reported as percentage in total population.
HC2: Hybrid Capture 2 (Qiagen, Hilden, Germany), PCR: polymerase chain reaction.
Kantathavorn et al. Infectious Agents and Cancer  (2015) 10:7 Page 8 of 9cervical cancer screening programs were not infected by
readily available vaccine-preventable HPV genotypes
(HPV16, HPV18, HPV6, and HPV11). This study thus
provides scientific evidence essential for the develop-
ment of appropriate HPV vaccination programs targeted
for certain HR-HPV genotypes prevalent in the Thai
women.
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